Review Article (Open access) |
---|
SSR Inst. Int. J. Life Sci., 8(2):
2981-2989,
March 2022
Relationship
between PCOS with Infertility and Insulin Sensitivity: A Review
Soumee Das1*,
Jifang Shi2
1PG Student, Department of Obstetrics and Gynecology,
Dali University, 671000, China
2Associate Professor, Department of Obstetrics and
Gynecology, Dali University, 671000, China
*Address for Correspondence: Dr. Soumee Das, Junior Resident, Department of Obstetrics and Gynecology,
Dali University, 671000, China
E-mail: soumeedasdlu18@yahoo.com
ABSTRACT- This
narrative review has brought forward the recent important findings of
polycystic ovary syndrome (PCOS) which is regarded as a prevalent endocrinological
and metabolic disorder with several clinical features. Treatment for PCOS
differs according to the presenting problems, underlying cause, age and
requirements of the individuals. The review has discussed the status of PCOS in
India separately, its etiologies, diagnosis and updated points of management.
The phenomena of Insulin Resistance and its management have been discussed by
reviewing various published works and the pathophysiologic relationship between
PCOS and infertility has been discussed in detail. The role of hyperinsulinemia
and Insulin Sensitivity in PCOS is discussed in detail with the relevant
pathophysiological mechanism. Overall, this review is clinically significant
and has discussed the essential points of a multisystem disorder (PCOS)..
Key
Words: Insulin
resistance, Infertility, PCOS, Polycystic ovary, Pathophysiologic relationshiP
INTRODUCTION-
Polycystic ovary syndrome or PCOS is one of the most prevalent endocrinological
and metabolic disorders, characterized by various clinical features including
excessive androgen production, menstrual abnormalities, hirsutism, etc.
Although the etiology is mostly unknown many studies have brought forward that
there is a relationship between this disorder and genetic and lifestyle factors. It is seen that females, who suffer
from infertility also show higher incidences of psychiatric disorders and
endometrial cancer as compared to females from general masses [1-10].
Yet the picture is still not clear if infertile women have greater chances of
developing cancer of mammary glands and ovaries as well [7,8,10–20].
But one fact is well established that PCOS women are at higher risk (than
normal females) of acquiring cardiovascular disorders along with metabolic
health complaints like diabetes [16,21–26].
Polycystic ovary
condition (PCOS) is one of the most commonly found endocrinological disorders
among females of reproductive age, manifested by hyperandrogenism, irregular
ovulation and ovulation. It is considered a metabolic disorder since it is
associated with a high occurrence of insulin resistance (IR), dyslipidemia,
obesity, and other metabolic abnormalities. The occurrence of PCOS can be as
high as 18% in reproductive females [27] and those with PCOS have a
higher risk of having infertility and other medical conditions [28].
Treatment for PCOS differs according
to the presenting problems, underlying cause, age and requirements of the
individuals. Those females, who are un-desirous of being pregnant, are treated
symptomatically to relieve them from menstrual irregularities, acne and
hirsutism [25-28].
PCOS in
India- A study
done on a population of 1000 females of South India [29], aged
between 18 to 24 years and comprising of both urban and rural population,
revealed that the incidence of PCOS is rising in cities and the urban women are
more prone to acquire PCOS by 0.1% as compared to the rural women. The study
showed that the overall incidence of PCOS in South India was 6% (as per
Rotterdam criteria). The study also revealed that the population of women was
at less risk of developing PCOS owing to their less consumption of junk food
and difference in lifestyle. Family history of PCOS, smoking, sedentary lifestyle,
and stress is a few of the other factors found to be associated with PCOS [28,29].
Etiologies, Diagnosis and Management
of PCOS- There are
many causes of female infertility. Most common etiologies are found to be
related to improper coordination of the hypothalamus-pituitary-ovarian axis. It
is seen that the components of the reproductive system like ovaries and
fallopian tubes and uterus should be optimized regarding their structure and
function because to achieve a healthy and successful conception there should be
synchrony in the anatomical and functional aspects of the components of the
female reproductive system [30]. Contraception is more common in
females of developed countries, or who have had many childbirths before, or
those who are starting their family at a mature age. So using intrauterine
birth control measures can cause infertility both due to inflammation and
damage of fallopian tubes [31,32]. The study observed that there
were 10.4% of those types of cases in which the cause of infertility could not
be defined identified despite full screening of both the male and female
partners and hence they were called infertility of unknown cause [33,34].
Other common causes of infertility include improper develop me displacement, of
the uterus, endometritis, atrophy and malignant neoplasm of the endometrium [34].
Infertility may also occur due to failure of the ovary to release the ovum at
the proper time and abnormality regarding implantation after fertilization
[35]. Another study showed that 20% of infertility occurs due to
menstrual disorders which can be accompanied by metabolic abnormalities. It
also established the role of the thyroid gland in hormone regulation of the
Hypothalamus-Pituitary-Ovary axis (HPO axis). Both over and under-functioning
thyroid glands are related to infertility. Besides this other lifestyle-related
elements and habits like active and passive smoking [36-39] by
females, stress, obesity, exposure to radiation and chemical agents are a few
more causes resulting in infertility.
Insulin Sensitivity and Its
Management- The state of systemic cellular response
towards the hormone insulin which maintains the glucose clearance is referred
to as Insulin Sensitivity (IS). Normal IS enables the cellular components of the
body of efficient usage of glucose present in the blood thus reducing it there
and maintaining a healthy and consistent glucose level in the blood. Insulin
plays an important role to regulate and maintain the level of glucose in the
bloodstream. The condition of when IS is reduced/ lowered is called Insulin
Resistance (IR) [38-40]. Under this circumstance, the mechanism of
glucose absorption by the cell gets impaired, leading to an increased sugar
level (glucose spike) in the blood. Without
proper treatment, this condition can predispose to Diabetes mellitus type II.
Abnormal levels of Insulin can impose a serious negative impact on fertility
and embryo-development in the early stages. Metabolic homeostasis is very
important for the achievement and accomplishment of a successful pregnancy.
Obesity and diabetes are some of the concerns of our modern lifestyle. In these
conditions, there is the consumption of high calories, which may result in
diminished reproductive capacity in females. Studies from bovine models have
revealed [40] that both situations whether energy excess or energy
deficit have associations with the level of insulin present in the body and
cause the follicular fluids to deviate from the normal limits [41].
Pathophysiologic
Relationship between PCOS and Infertility- PCOS is
self-descriptive and suggests an ovary having multiple cysts. This clinical
condition causes irregular menstrual cycle, amenorrhoea and hirsutism in
females [42]. Recently the definition has expanded due to the
incorporation of four different phenotypes [43] along with causes of
monogenic causes of hirsutism and oligomenorrhea, accompanied with baldness
similar to that of males [44]. But the monogenic cause was soon
terminated as studies on twins on small cohorts of mono- and dizygotic twin
pairs revealed that PCOS is a polygenic disorder linked with the X chromosome
and not an autosomal dominant or monogenic kind of disorder [45,46].
Another study established that there was a ‘72% variance in risk of PCOS’ which
exhibited genetic involvement [47].
Defects in the insulin signaling pathway
have been found to have an association with PCOS [48]. PCOS can
change the insulin gene expression pathway [49]. A different type of
pathway related to cellular oxidative stress has come up with a possible
explanation of PCOS pathology [50]. Oxidative stress can also
trigger hypergonadism [51].
Classification
Based on Phenotype- Recently, the definition of PCOS has
become more elaborative and encompasses 4 types of PCOS phenotypes, namely A-D.
According to the general rule hyperandrogenism, BMI [52], irregular
menses [53] are independent predictors indicating a metabolic
malfunction. Rather ovarian morphology has a lesser role to play here.
PCOS
Phenotypes A and B- Also called classic PCOS. Women with
these subtypes suffer from irregular menstruation, increased insulin production
and IR and are at greater risk of developing metabolic syndrome. These women
are more prone to have obesity and atherogenic dyslipidemia [54].
They are at greater risk of developing hepatic steatosis when compared with
healthy controls [55]. The classic PCOS women additionally display
an extravagant elevated amount of anti-mullerian hormone (AMH) [56].
Phenotype C is also called ovulatory PCOS and typically presents the features
of slightly increased insulin, atherogenic lipids, and higher levels of
androgens. It is found to be associated with hirsutism and impaired metabolic
functions [57].
In 2009, a study with cohort design
mentioned that phenotype C is the most prevalent one [58]. Food,
rich in oil and calorie, leading to increased accumulation of fat can be the
possible explanation for Khan et al. [59].
Phenotype D is known as Non-hyperandrogenic PCOS and it is characterized by a
normal level of androgen with slightly imbalanced overall endocrine status and
minimal metabolic dysfunction [60,61] in comparison to healthy
controls [62,63]. Non-androgenic hormones like Sex hormone-binding
globulin (SHBG), T3, T4, decreased LH/FSH ratio have been found to have an association
with PCOS type D, as compared with classic PCOS [64]. Usually,
patients with PCOS type D experience consistent menstrual cycles with
occasional abnormalities [65].
But this classification is not universally
accepted as PCOS is a multifaceted and complicated disease; there are few
exceptions that can also be considered. A German study of different types of
PCOS exhibited no noticeable differences in IR, dyslipidemia, or BMI [66].
Another study from Greece showed similar findings [66], which has
found IR in those patients whose BMI was found to be more than 25 kg/m2
[67]. Again, studies in Sri Lanka and Brazil exhibited no such
significant variation in metabolic syndrome in females suffering from PCOS [68,69].
Role of Insulin Sensitivity in PCOS-
Hyperinsulinemia
causes virilization affecting granulosa cells (found in theca cells & small
follicles) and can induce premature ripening of immature follicles mediated by
Luteinising Hormone resulting in an ovulation [70-72]. This
situation can be improved by employing insulin‐sensitizing agents like
the biguanide class of drugs (Metformin) and thiazolidinedione derivatives [73].
Hyperinsulinemia has an antagonistic effect on the endometrium both functionally
and environmentally. It is also one of the leading causes of failure of
implantation [74]. This condition can be treated with metformin,
which enhances insulin sensitivity. Metformin is a potent agent to improve
functions of 'levels of glycodelin, which is an Insulin‐like Growth
Factor (IGF) binding protein. It can effectively maintain the blood supply in
the spiral arteries during peri‐implantation.
The efficacy of Metformin in treating infertility is due to its effects on the structural and functional maintenance of the endometrium and assistance in implantation of the developing embryo [72]. Studies have pointed out that 30–50% of women with PCOS are more vulnerable to pregnancy loss in the first 3 months, which is said to be three times greater than normal pregnant women [75,76].
Using Metformin
as a medication can reduce insulin levels in blood regulates plasminogen
activator inhibitor activity. Hence it can reduce the risk of failure of early
pregnancy. Lifestyle change is one of the fundamental measures for improving
reproductive performance in addition to treatment with insulin‐sensitizing
agents. The inclusion of the Metformin regimen leads to the decreased rate of
early pregnancy failure to 8.8% as compared to the control group with PCOS
having the rate of early pregnancy loss is up to 41.9% [77].
Metformin
regimen not only improves IS but also reduces the chance of losing an early
pregnancy in patients with PCOS. Metformin is non-teratogenic and hence is safe
for pregnant women [78].
Current Management Approaches of
Improving Insulin Sensitivity- For young women who
have PCOS the primary line of treatment is helping them to achieve pregnancy
resulting in a successful live birth. In such patients, the first line of
ovulation-inducing drugs used commonly is clomiphene citrate (CC), letrozole
(LZ), and metformin [79]. CC is capable of inducing ovulation and it
is anti-estrogen and non-steroidal [80]. LZ is a type of aromatase
inhibitor and its function is to prevent
the conversion of androgens (secreted by adrenal glands) to estrogens. Although
better known for its anti-tumour properties, which can effectively treat breast
cancer [81].It additionally exhibits the properties of an ovulation
induction agent. Metformin, a hypoglycemic drug that is generally used in
treating diabetes [82] is also known for its features as an inducer
of ovulation and improvement of pregnancy rate in women having PCOS [83,84].
A meta-analysis [85] found it to be less potent than CC. The
beneficial effect of Metformin in PCOS is yet to explore. It might be possible
that Metformin further develops insulin sensitivity (IS) in the liver and
peripheral tissues, which might be the instrument clarifying its impact in
further developing pregnancy in PCOS women. With the help of studies with
larger samples, it has been established that insulin resistance is prevalent in
almost 44%–70% of females with PCOS [86].
Results
extracted from familial aggregation studies reveal that PCOS can be inherited
and that those gene variants that cause IR can be readily detected in PCOS
patients. Other than this ‘intra-uterine growth restriction (IUGR) and small
for gestational age (SGA') may result in the hypersecretion of glucocorticoids
that increases the risk of developing obesity and hyperinsulinemia among
children [87]. Under such situations when supra-physiological
insulin was deployed it resulted in enhanced ‘steroid-genesis, derange
granulosa cell differentiation, with influence on the growth of follicle [88].
But, full assurance that drugs inducing IS in PCOS and help in getting them
pregnant has not been achieved [89]. But according to another school
of thought, various Randomized Control Trials (RCTs) brought forward that CC
and other non-diabetic medicines are efficient and beneficial in IS and on the
attainment of higher clinical pregnancy rate [90,91].
About 5-10% of reproductive females have been found suffering from PCOS. Lifestyle change and reduction in body weight are vital to effectively managing PCOS. Hirsutism can be managed by using contraceptive pills, while the severe form of it will additionally need ‘anti-androgens /estrogen-progestin therapy (Combined contraceptive pills or COCP). Another reason for ovulatory infertility reacts pretty well to clomiphene citrate when trailed with gonadotropins in minimal dosages. Also, drugs that enhance insulin sensitivity have been seen to help in achieving good ovulatory performance. One such natural compound is inositol which is at par with metformin with the additional advantage of imposing lesser counter effects. Other natural and sustainable naturally occurring statins, like monacolin, can be used as mono or dual therapy (Myo-inositol) to reduce the hyperandrogenic levels in the sufferers with the least counter effects [92,93]. Although Metformin is an effective line of treatment of PCOS for obese adolescents (also suffering from hyperandrogenemia) milder phenotypes of PCOS may not exhibit the similar pattern of IR thus presenting us the new insight that insulin-sensitizing drugs may not qualify as optimum therapy in all cases of PCOS and so the treatment should be targeted towards specific metabolic or reproductive problems [94].
A recent study, Laganà et al.[95] have concluded that ingestion of insulin second messengers like Myo-inositol (MI) and D-chiro-inositol (DCI) can be beneficial to increase IS, as MI plays an important role in follicular gonadotropin pathways which coordinates and manages ovulation. MI/DCI ratio is tissue-specific and insulin is known to modulate it by aromatase this system loses its balance when the body shows signs of insulin resistance (IR), and hence epimerization of MI to DCI in insulin-sensitive tissues accordingly diminishes. This MI/DCI ratio in the ovaries is 100: 1, but its level decreases vividly and the causative reason behind this presence is an ‘insulin-stimulated epimerase in hyperinsulinemic women with PCOS. Thus using Inositols have been seen as very fruitful in PCOS, as it brings about multi-faced improvement at the metabolic level, hormonal level refurbishes spontaneous ovulation. Studies on assisted reproductive technology have approved that ovarian stimulation parameters can be improved by inositol yet half-heartedly, thus further works on ‘spontaneous and non-spontaneous fertility’ need to be taken. Oral supplementation with MI, DCI, or their combination can improve Metabolic functioning and restoration of normal ovarian functioning in PCOS can be well achieved when they are exposed to oral dosages of MI/ DCI/ combination of both. The ideal MI: DCI ratio is 40: 1 encourages the success of fertility as an excess of DCI might be deleterious for oocyte development. Thus despite conflicting evidence, inositols stand as a promising treatment for PCOS [95].
PCOS patients are much fragile to being obese and obesity [96] is known to disrupt their metabolic, endocrine, and reproductive functions. Many anti-obesity drugs like ‘orlistat, sibutramine, and rimonabant can be incorporated into a regime of PCOS patients but except orlistat, the other two are out of circulation due to their harmful potentials and orlistat shines bright in the life of overweight and obese diabetic patients as it induced faster weight loss and rendered metabolic and cardiovascular benefits that were impossible to achieve through lifestyle changes alone [96].
CONCLUSIONS- This review has discussed all the possible aspects
of PCOS, whose prevalence has become clinically significant for conducting
research. Many experimental studies are being conducted to bring new
information and findings of PCOS. These newly emerged findings are updated from
time to time. Clinicians need to remain updated with the several aspects of
PCOS. The prevalence of this disorder is such that clinicians of the entire
speciality should be informed regarding the aspects of PCOS. This multi-system
disorder can affect several organ systems and the prognosis can be fatal if not
managed effectively.
The drug
regimens are getting updated to make the prognosis better than ever. Early
diagnosis and effective management are essential to bring a better prognosis
and to manage any other chronic condition. The intention of this review article
is the need of the hour for the medical community.
CONTRIBUTION OF AUTHORS
Research concept-
Soumee Das
Research design- Soumee
Das
Supervision-Shi
Ji Fang
Materials- Soumee
Das
Data collection- Soumee
Das
Data analysis and Interpretation- Soumee Das
Literature search- Soumee Das
Writing article- Soumee
Das
Critical review- Shi
Ji Fang
Article editing- Shi
Ji Fang
Final
approval- Shi Ji Fang
REFERENCES
1.
Valoriani VFL, Lari D, Miccinesi G,
Vaiani S, Vanni C, et al. Differences in psychophysical well-being and signs of
depression in couples undergoing their first consultation for assisted
reproduction technology (ART): an
Italian pilot study. Europ J Obstet Gynecol Reprod Biol., 2016; 197: 179–85.
2.
Veltman-Verhulst S. Emotional distress
is a common risk in women with polycystic ovarian syndrome: a systematic review and meta-analysis of 28
studies. Hum Reprod Update, 2012; 18(6): 638–51.
3.
Gokhan A. Level of anxiety, depression,
self esteem, social anxiety, and quality of life among women with polycystic
ovarian syndrome. Sci World J., 2013; 2013: 7.
4.
Jedel E. Anxiety and depression symptoms
in women with polycystic ovarian syndrome compared with controls matched for
body mass index. Hum Reprod., 2009; 25(2): 450–56.
5.
Baldur-Felskov P. disorders in women
with fertility problems: results from a
large Danish register-based cohort study. Hum Reprod., 2013; 28(3): 683–90.
6.
Hart RDD. The potential implications of
a PCOS diagnosis on a woman’s long-term health using data linkage. J Clin
Endocrinol Metab., 2015; 100(3): 911–19.
7.
Venn A. Risk of cancer after use of
fertility drugs with in vitro
fertilization. Lancet, 1999; 354(9190): 1586–90.
8.
Barry J. Risk of endometrial, ovarian,
and breast CA in women with polycystic ovarian syndrome: a systematic review and meta-analysis. Hum
Reprod Update, 2014; 20(5): 748-58.
9.
Brinton L. Fertility drugs and
endometrial cancer risk: results from an
extended follow up from a large infertility cohort. Hum Reprod., 2013; 28(10):
2813–21.
10. Venn
A. Breast and ovarian cancer incidence after infertility and in vitro fertilization. Lancet, 1995;
346(8981): 995–100.
11. Lundberg
F. Association of infertility and fertility treatment with mammographic density
in a large screening-based cohort of women:
a cross-sectional study. Breast Cancer Res., 2016; 18(1): 36.
12. Kim
J. Polycystic ovarian syndrome (PCOS), related symptoms/sequelae, and breast
cancer risk in a population based case-control study. Cancer Causes Control,
2016; 27(3): 403–14.
13. Gabriele
V. Infertility and breast cancer: is
there a link? Updated review of the literature and meta-analysis. Gynecol
Obstet Fertil., 2016; 44(2): 113–20.
14. Reigstad
M. Risk of breast cancer following fertility treatment-a registry based cohort
study of parous women in Norway. Int J Cancer, 2015; 136(5): 1140–48.
15. Reigstad
M. Cancer risk among parous women following assisted reproductive technology.
Hum Reprod., 2015; 30(8): 1952–63.
16. Kvaskoff
M. Endometriosis: a high risk population
for major chronic diseases? Hum Reprod Update, 2015; 21(4): 500–16.
17. Luke
B. Cancer in women after assisted reproductive technology. Fertil Steril.,
2015; 104(5): 1218–26.
18. Cirillo
P, et al. Irregular menses predicts ovarian cancer: Prospective evidence from
the Child Health and Development Studies. Int J Cancer, 2016; 139(5): 1009-17.
doi: 10.1002/ijc.30144.
19. Bjornholt
S. Risk for borderline ovarian tumors after fertility drugs: results of a population based cohort study.
Hum Reprod., 2015; 30(1): 222–31.
20. Rizzuto
I. Risk of ovarian cancer in women treated with ovarian stimulating drugs for
infertility. Cochrane Database Syst Rev., 2013: 8.
21. Parikh
N, et al. Reproductive risk factors and coronary heart disease in the Women’s
Health Initiative Observational Study. Circulation, 2016;133(22): 2149-58.
22. Ghaffarzad
A. Correlation of serum lipoprotein ratios with insulin resistance in infertile
women with PCOS: a case control study.
Int J Fertil Steril., 2016; 10(1): 29–35.
23. El-Hayek,
et al. Polycystic ovarian syndrome: An updated overview. Front Physiol., 2016;
7: 124.
24. Polat
S. Thyroid disorders in young females with PCOS and correlation of thyroid
volume with certain hormonal parameters. J Reprod Med., 2016; 61(1–2): 27–32.
25. Zahiri
Z. Metabolic syndrome in patients with polycystic ovarian syndrome in Iran. Int
J Fertil Steril., 2016; 9(4): 490–96.
26. Ramezani-Binabaj
M. Are women with polycystic ovarian syndrome at high risk of non-alcoholic
fatty liver disease; a meta-analysis. Hepat Mon., 2014; 14: 11.
27. March
WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, et al. The prevalence of
polycystic ovary syndrome in a community sample assessed under contrasting
diagnostic criteria. Hum Reprod., 2010; 25(2): 544–51. doi: 10.1093/humrep/dep399.
28. Nandi
A, Chen Z, Patel R, Poretsky L. Polycystic ovary syndrome. Endocrinol
Metab Clin North Am., 2014; 43(1): 123–47. doi:
10.1016/j.ecl.2013.10.003.
29. Bharathi
RV, Swetha S, Neerajaa J, Madhavica JV, Janani DM, et al. An epidemiological
survey: Effect of predisposing factors for PCOS in Indian urban and rural
population. Middle East Fertil Soc J., 2017; 22(4): 313-16.
30. Speroff
L, Glass R, Kase N. Clinical Gynecological Endocrinology and Infertility –
Lippincott Williams and Wilkins 1999, U.S.A., pp. 1035-36.
31. Tsevat
DG, Wiesenfeld HC, Parks C, Peipert JF. Sexually transmitted diseases and
infertility. Am J Obstet Gynecol., 2017; 216(1): 1-9. doi:
10.1016/j.ajog.2016.08.008.
32. Stoddard
AM, Xu H, Madden T, Allsworth JE, Peipert JF. Fertility after intrauterine
device removal: a pilot study. Eur J Contracept Reprod Health Care, 2015;
20(3): 223-30. doi: 10.3109/13625187.2015.1010639.
33. Hart
R. Unexplained infertility, endometriosis and fibroids. BMJ, 2003; 327(7417):
721-24.
34. Sépaniak
S, Forges T, Monnier-Barbarino P. Cigarette smoking and fertility in women and
men. Gynecol Obstet Fertil., 2006; 34(10): 945-49.
35. Roupa
Z, Polikandrioti M, Sotiropoulou P, Faros E, Koulouri A, et al. Causes of
Infertility in Women at Reproductive Age. Health Sci J., 2009; 3: 2.
36. Practice
Committee of the American Society for Reproductive Medicine. Smoking and
infertility. Fertil Steril., 2006; 86(5S): S172-77.
37. Berthiller
J., Sasco AJ. Smoking (active or passive) in relation to fertility, medically
assisted procreation and pregnancy. J Gynecol Obstet Biol Reprod., 2005; 34(1):
47-54.
38. de
Mouzon J, Belaisch-Allart J. Consequences on women's fecundity and on assisted
reproductive technology. J Gynecol Obstet Biol Reprod., 2005; 34(1): 112-18.
39. Soares
SR, Simon C, Remohí J, Pellicer A. Cigarette smoking affects uterine
receptiveness. Hum Reprod., 2007; 22(2): 543-47.
40. Laskowski
D, Sjunnesson Y, Humblot P, Andersson G, Gustafsson H, et al. The functional
role of insulin in fertility and embryonic development—What can we learn from
the bovine model?. Theriogenol., 2016; 86(1): 457-64.
41. Fruzzetti
F, Perini D, Russo M, Bucci F, Gadducci A. Comparison of two insulin
sensitizers, metformin and myo-inositol, in women with polycystic ovary
syndrome (PCOS). Gynecol Endocrinol., 2017; 33(1): 39-42.
42. Zawadzki
JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rationale approach. Polycystic
Ovary Syndrome, 1992.
43. Crespo
RP, Bachega TASS, Mendonça BB, Gomes LG. An update of genetic basis of
PCOS pathogenesis. Arch Endocrinol Metab., 2018; 62: 352–61. doi:
10.20945/2359-3997000000049.
44. Carey
AH, Chan KL, Short F, White D, Williamson R, et al. Evidence for a single
gene effect causing polycystic ovaries and male pattern baldness. Clin
Endocrinol (Oxf). 1993; 38: 653–58. doi: 10.1111/j.1365-2265.1993.tb02150.x.
45. Jahanfar
S, Eden JA, Warren P, Seppala M, Nguyen TV. A twin study of polycystic
ovary syndrome. Fertil Steril., 1995; 63: 478–86.
46. Jahanfar
S, Eden JA, Nguyen T, Wang XL, Wilcken DEL. A twin study of polycystic
ovary syndrome and lipids. Gynecol Endocrinol., 1997; 11: 111–17. doi:
10.3109/09513599709152521.
47. Vink
JM, Sadrzadeh S, Lambalk CB, Boomsma DI. Heritability of polycystic ovary
syndrome in a Dutch twin-family study. J Clin Endocrinol Metab., 2006;
91(6): 2100-04. doi: 10.1210/jc.2005-1494.
48. Dunaif
A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for
pathogenesis. Endocr Rev., 1997; 7: 345–49.
49. Cortón
M, Botella-Carretero JI, Benguría A, et al. Differential gene expression
profile in omental adipose tissue in women with polycystic ovary
syndrome. J Clin Endocrinol Metab., 2007; 92: 328–37. doi:
10.1210/jc.2006-1665.
50. González
F, Rote NS, Minium J, Kirwan JP. Reactive oxygen species-induced oxidative
stress in the development of insulin resistance and hyperandrogenism in
polycystic ovary syndrome. J Clin Endocrinol Metab., 2006; 91: 336–40.
doi: 10.1210/jc.2005-1696.
51. Victor
VM, Rocha M, Bañuls C, et al. Mitochondrial complex I impairment in
leukocytes from polycystic ovary syndrome patients with insulin
resistance. J Clin Endocrinol Metab., 2009; 94: 3505–12. doi:
10.1210/jc.2009-0466.
52. Ehrmann
DA, Liljenquist DR, Kasza K, et al. Prevalence and predictors of the
metabolic syndrome in women with polycystic ovary syndrome. J Clin
Endocrinol Metab., 2006; 91: 48–53. doi: 10.1210/jc.2005-1329.
53. Brower
M, Brennan K, Pall M, Azziz R. The severity of menstrual dysfunction as a
predictor of insulin resistance in pcos. J Clin Endocrinol Metab., 2013;
98: E1967–71. doi: 10.1210/jc.2013-2815.
54. Lizneva
D, Suturina L, Walker W, Brakta S, Gavrilova-Jordan L, et al. Criteria,
prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril.,
2016; 106: 6–15. doi: 10.1016/j.fertnstert.2016.05.003.
55. Goverde
AJ, Van Koert AJB, Eijkemans MJ, et al. Indicators for metabolic
disturbances in anovulatory women with polycystic ovary syndrome diagnosed
according to the Rotterdam consensus criteria. Hum Reprod., 2009; 24:
710–17.
56. Sahmay
S, Atakul N, Oncul M, Tuten A, Aydogan B, et al. Serum anti-mullerian
hormone levels in the main phenotypes of polycystic ovary syndrome. Eur J
Obstet Gynecol Reprod Biol., 2013; 170: 157–61. doi:
10.1016/j.ejogrb.2013.05.019.
57. Guastella
E, Longo RA, Carmina E. Clinical and endocrine characteristics of the main
polycystic ovary syndrome phenotypes. Fertil Steril., 2010; 94: 2197–201.
doi: 10.1016/j.fertnstert.2010.02.014.
58. Di
Fede G, Mansueto P, Longo RA, Rini G, Carmina E. Influence of
sociocultural factors on the ovulatory status of polycystic ovary syndrome. Fertil
Steril., 2009; 91: 1853–56. doi: 10.1016/j.fertnstert.2008.02.161
59. Khan
MJ, Ullah A, Basit S. Genetic basis of polycystic ovary syndrome (PCOS): current perspectives. The application of
clinical genetics, 2019; 12: 249.
60. Zhang
HY, Zhu FF, Xiong J, Shi XB, Fu SX. Characteristics of different
phenotypes of polycystic ovary syndrome based on the Rotterdam criteria in a
large-scale Chinese population. BJOG an Int J Obstet Gynaecol., 2009; 116:
1633–39. doi: 10.1111/j.1471-0528.2009.02347.x.
61. Dewailly
D, Catteau-Jonard S, Reyss A-C, Leroy M, Pigny P. Oligoanovulation with
polycystic ovaries but not overt hyperandrogenism. J Clin Endocrinol
Metab., 2006; 91: 3922–27. doi: 10.1210/jc.2006-1054.
62. Zhuang
J, Liu Y, Xu L, et al. Prevalence of the polycystic ovary syndrome in
female residents of chengdu, china. Gynecol Obstet Invest., 2014; 77:
217–23. doi: 10.1159/000358485.
63. Yilmaz
M, Isaoglu U, Delibas IB, Kadanali S. Anthropometric, clinical and
laboratory comparison of four phenotypes of polycystic ovary syndrome based on
Rotterdam criteria. J Obstet Gynaecol Res., 2011; 37: 1020–26. doi:
10.1111/jog.2011.37.issue-8.
64. Jamil
AS, Alalaf SK, Al-Tawil NG, Al-Shawaf T. Comparison of clinical and
hormonal characteristics among four phenotypes of polycystic ovary syndrome
based on the Rotterdam criteria. Arch Gynecol Obstet., 2016; 293: 447–56.
doi: 10.1007/s00404-015-3889-5.
65. Panidis
D, Tziomalos K, Papadakis E, et al. Associations of menstrual cycle
irregularities with age, obesity and phenotype in patients with polycystic
ovary syndrome. Hormones, 2015. doi: 10.14310/horm.2002.
66. Cupisti
S, Haeberle L, Schell C, et al. The different phenotypes of polycystic
ovary syndrome: no advantages for
identifying women with aggravated insulin resistance or impaired
lipids. Exp Clin Endocrinol Diabetes, 2011; 119: 502–08. doi:
10.1055/s-0031-1277136 .
67. Panidis
D, Tziomalos K, Misichronis G, et al. Insulin resistance and endocrine
characteristics of the different phenotypes of polycystic ovary syndrome: a prospective study. Hum Reprod., 2012;
27: 541–49. doi: 10.1093/humrep/der418.
68. Wijeyaratne
CN, Seneviratne RDA, Dahanayake S, et al. Phenotype and metabolic profile
of South Asian women with polycystic ovary syndrome (PCOS): results of a large database from a specialist
endocrine clinic. Hum Reprod., 2011; 26: 202–13. doi:
10.1093/humrep/deq310.
69. Melo
AS, Vieira CS, Romano LGM, Ferriani RA, Navarro PA. The frequency of
metabolic syndrome is higher among PCOS Brazilian women with menstrual
irregularity plus hyperandrogenism. Reprod Sci., 2011; 18: 1230–36. doi:
10.1177/1933719111414205.
70. Ates
S, Sevket O, Sudolmus S, et al. Different phenotypes of polycystic ovary
syndrome in Turkish women: clinical and
endocrine characteristics. Gynecol Endocrinol., 2013; 29: 931–35. doi:
10.3109/09513590.2013.819082.
71. Rosner
W, Auchus RJ, Azziz R, Sluss PM, Raff H. Position statement: utility, limitations, and pitfalls in
measuring testosterone: an endocrine
society position statement. J Clin Endocrinol Metab., 2007; 92: 405–13. doi:
10.1210/jc.2006-1864
72. Sakumoto
T, Tokunaga Y, Tanaka H, Nohara M, Motegi E, Shinkawa T, et al. Insulin
resistance/hyperinsulinemia and reproductive disorders in infertile
women. ReprodMed Biol., 2010; 9(4): 185-90.
73. Azziz
R, Ehrmann D, Legro RS, Whitcomb RW, Hanley R, Fereshetian AG, O'keefe M,
Ghazzi MN. Troglitazone improves ovulation and hirsutism in the polycystic
ovary syndrome: a multicenter, double
blind, placebo‐controlled trial. J Clin Endocrinol Metab.,
2001; 86: 1626–32. doi: 10.1210/jc.86.4.1626.
74. Ben‐Haroush
A, Yogev Y, Fisch B. Insulin resistance and metformin in polycystic ovary
syndrome. Eur J Obstet Gynecol Reprod Biol., 2004; 115: 125-133.
doi: 10.1016/j.ejogrb.2003.11.027.
75. Regan
L, Owen EJ, Jacobs HS. Hypersecretion of luteinising hormone, infertility,
and miscarriage. Lancet, 1990; 336:
1141–44. doi: 10.1016/0140‐6736(90)92765‐A.
76. Gray
HR, Wu LY. Subfertility and risk of spontaneous abortion. Am J Public
Health, 2000; 90:1452–54. doi: 10.2105/AJPH.90.9.1452.
77. Jakubowicz
DJ, Iuorno MJ, Jakubowicz S, Roberts KA, Nestler JE. Effects of metformin
on early pregnancy loss in the polycystic ovary syndrome. J Clin
Endocrinol Metab., 2002; 87: 524–29. doi: 10.1210/jc.87.2.524.
78. Glueck
CJ, Wang P, Goldenberg N, Sieve‐Smith L. Pregnancy outcomes among women
with polycystic ovary syndrome treated with metformin. Hum Reprod.,
2002; 17: 2858-64. doi: 10.1093/humrep/17.11.2858.
79. Teede
HJ, Misso ML, Costello MF, Dokras A, Laven J, et al. Recommendations from the
international evidence-based guideline for the assessment and management of
polycystic ovary syndrome. Hum Reprod., 2018; 33(9): 1602–18. doi:
10.1093/humrep/dey256.
80. Homburg
R. Clomiphene citrate–end of an era? A mini-review. Hum
Reprod., 2005; 20(8): 2043–51. doi:
10.1093/humrep/dei042.
81. Dellapasqua
S, Colleoni M. Letrozole. Expert Opin Drug Metab Toxicol., 2010;
6(2): 251–59. doi:
10.1517/17425250903540246.
82. Buse
JB, Wexler DJ, Tsapas A, Rossing P, Mingrone G, et al. Management of
Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American
Diabetes Association (ADA) and the European Association for the Study of
Diabetes (EASD). Diabetes Care, 2020; 43(2): 487–93. doi:
10.2337/dci19-0066.
83. Asrm
Asrm Org Practice Committee of the American Society for Reproductive Medicine.
Electronic Address and Medicine Practice Committee of the American Society for
Reproductive, Role of metformin for ovulation induction in infertile patients
with polycystic ovary syndrome (PCOS): a
guideline. Fertil Steril., 2017; 108(3): 426–41. doi:
10.1016/j.fertnstert.2017.06.026.
84. Tang
T, Lord JM, Norman RJ, Yasmin E, Balen AH. Insulin-sensitising drugs
(metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with
polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane
Database Syst Rev., 2012; 2012(5): CD003053. doi: 10.1002/14651858.CD003053.pub5.
85. Siebert
TI, Viola MI, Steyn DW, Kruger TF. Is metformin indicated as primary ovulation
induction agent in women with PCOS? A systematic review and
meta-analysis. Gynecol Obstet Invest., 2012; 73(4): 304–13. doi: 10.1159/000335253.
86. Li
W, Chen Q, Xie Y, Hu J, Yang S, Lin M. Prevalence and degree of insulin
resistance in Chinese Han women with PCOS:
Results from euglycemic-hyperinsulinemic clamps. Clin Endocrinol.,
2019; 90(1): 138–44. doi: 10.1111/cen.13860.
87. De
Melo AS, Dias SV, Cavalli Rde C, Cardoso VC, Bettiol H, et al. Pathogenesis of
polycystic ovary syndrome:
multifactorial assessment from the foetal stage to
menopause. Reprod., 2015; 150(1): R11–24. doi: 10.1530/REP-14-0499.
88. Franks
S, Stark J, Hardy K. Follicle dynamics and anovulation in polycystic ovary
syndrome. Hum Reprod Update, 2008; 14(4): 367–78. doi: 10.1093/humupd/dmn015.
89. Morley
LC, Tang T, Yasmin E, Norman RJ, Balen AH. Insulin-sensitising drugs
(metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with
polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane
Database Syst Rev., 2017; 11: CD003053. doi:
10.1002/14651858.CD003053.pub6.
90. Ng
EHY, Wat NMS, Ho PC. Effects of metformin on ovulation rate, hormonal and
metabolic profiles in women with clomiphene-resistant polycystic ovaries: A randomized, double-blinded
placebo-controlled trial. Hum Reprod., 2001; 16(8): 1625–31. doi: 10.1093/humrep/16.8.1625.
91. Nemati
M, Nemati S, Taheri AM, Heidari B. Comparison of metformin and N-acetyl
cysteine, as an adjuvant to clomiphene citrate, in clomiphene-resistant women
with polycystic ovary syndrome. J Gynecol Obstet Hum Reprod., 2017; 46(7):
579–85. doi: 10.1016/j.jogoh.2017.07.004.
92. Liu
Y, Li J, Yan Z, Liu D, Ma J, et al. Improvement of Insulin Sensitivity
Increases Pregnancy Rate in Infertile PCOS Women: A Systemic Review. Front
Endocrinol., 2021; 12: 317.
93. Morgante G, Massaro MG, Di Sabatino A, Cappelli V, De Leo V.
Therapeutic approach for metabolic disorders and infertility in women with
PCOS. Gynecological Endocrinol., 2018;
34(1): 4-9.
94. Marshall JC, Dunaif A. Should all women with PCOS be treated
for insulin resistance?. FertilSteril., 2012;
97(1): 18-22.
95. Laganà AS, Garzon S, Casarin J, Franchi M, Ghezzi F. Inositol
in polycystic ovary syndrome: restoring fertility through a
pathophysiology-based approach. Trends
Endocrinol Metabol., 2018; 29(11):
768-80.
96. Panidis D, Tziomalos K, Papadakis E, Vosnakis C, Chatzis P,
et al. Lifestyle intervention and anti-obesity therapies in the polycystic
ovary syndrome: impact on metabolism and
fertility. Endocr., 2013;
44(3): 583-90.